Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open-label, Single-arm, Multicenter Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia

NCT07084831 is registered in ClinicalTrials.gov with European Group for Research In Schizophrenia as lead sponsor.

NCT NCT07084831
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07084831 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open-label, Single-arm, Multicenter Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia
Lead sponsor
European Group for Research In Schizophrenia
Phase
Phase 3
Overall status
Not yet recruiting
Start date
January 1, 2027
Completion date
July 1, 2029
Enrollment
171 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

cognitive impairment, schizophrenia; psychosis